HIV11: Sexually Transmitted HCV Rising among HIV+ Gay Men in Europe, but More Are Getting Treated
- Details
- Category: HCV Prevention
- Published on Friday, 14 December 2012 00:00
- Written by Liz Highleyman
Hepatitis C virus (HCV) infection rates continue to rise among HIV positive people in Europe, with the highest incidence among injection drug users and men who have sex with men, researchers reported at the 11th International Congress on Drug Therapy in HIV Infection last month in Glasgow. Another study, however, found that HIV/HCV coinfected people are now more likely to receive hepatitis C treatment.
HIV11: Lipid Levels Are Higher among HIV+ People on ART, Immune Suppression May Play a Role
- Details
- Category: HIV Treatment
- Published on Friday, 14 December 2012 00:00
- Written by Liz Highleyman
People with HIV on suppressive antiretroviral therapy (ART) have "considerably higher" blood lipid levels relative to untreated individuals or those on less effective treatment, researchers reported at the 11th International Congress on Drug Therapy in HIV Infection (HIV11) last month in Glasgow. They also found that greater immune deficiency, as indicated by lowest-ever CD4 count, was associated with lipid elevations.
HIV11: New Studies Challenge Evidence of Reduced Abacavir Potency When Viral Load Is High
- Details
- Category: HIV Treatment
- Published on Friday, 30 November 2012 00:00
- Written by Gus Cairns
An analysis of 2 studies of the new HIV integrase inhibitor dolutegravir presented at the 11th International Congress on Drug Therapy in HIV Infection this month in Glasgow had the incidental effect of bringing into question evidence from a previous study suggesting that the nucleoside reverse transcriptase inhibitor abacavir (Ziagen, also in the Epzicom or Kivexa coformulation) was less potent in people starting HIV therapy with high viral loads than another NRTI drug, tenofovir (Viread, also in the Truvada, Atripla, Complera, and Stribild coformulations). 
Liver Toxicity Uncommon with Modern Antiretroviral Drugs, but Higher Risk for HIV/HCV Coinfected
- Details
- Category: HIV Treatment
- Published on Wednesday, 05 December 2012 00:00
- Written by Liz Highleyman
Recently approved antiretroviral drugs are generally well-tolerated and seldom cause serious liver enzyme elevations, although protease inhibitors are somewhat more likely to do so, researchers reported in the November 28, 2012, advance online edition of AIDS. People with HIV/HCV coinfection are more likely to experience liver toxicity, however, and early hepatitis C treatment may improve the tolerability of HIV therapy.
HIV11: Stribild Matches Efficacy and Tolerability of Atripla or Boosted Atazanavir at 96 Weeks
- Details
- Category: HIV Treatment
- Published on Tuesday, 27 November 2012 00:00
- Written by Liz Highleyman
The Stribild single-tablet-regimen -- formerly dubbed the Quad -- demonstrated "robust and durable" efficacy and continued to be well-tolerated through 96 weeks, according to findings from 2 studies presented at the 11th International Congress on Drug Therapy in HIV Infection (HIV11) this month in Glasgow. 
More Articles...
- HIV11: UK Study Finds HIV+ Women on Antiretroviral Therapy Have Higher Premature Birth Rate
- HIV11: Life Expectancy in Older People with HIV Could Exceed the Average - As Long As ART Keeps Working
- HIV11: Complera Combo Pill as Effective as Atripla for First HIV Treatment, but Better Tolerability
- Coverage of 11th International Congress on Drug Therapy in HIV Infection
Web Design and Development by